PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program
PepGen will present clinical data from its PGN-EDODM1 program at the 15th International Myotonic Dystrophy Consortium (IDMC-15) in late May 2026. The company highlighted a late-breaking oral presentation featuring individual patient mis-splicing analyses and a poster session on the FREEDOM-DM1 trial, which reportedly demonstrated strong splicing correction with single doses.
Key figures
- Drug Name
- PGN-EDODM1
- Phase Of Trial
- Phase 1/2 (implied by SAD/MAD and FREEDOM-DM1 context)
- Patient population us eu
- 115,000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.